Edgestream Partners L.P. Buys Shares of 19,678 Krystal Biotech, Inc. $KRYS

Edgestream Partners L.P. purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,678 shares of the company’s stock, valued at approximately $2,705,000. Edgestream Partners L.P. owned 0.07% of Krystal Biotech at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in KRYS. Brooklyn Investment Group grew its holdings in shares of Krystal Biotech by 291.7% in the first quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock valued at $25,000 after purchasing an additional 105 shares in the last quarter. Twin Tree Management LP purchased a new position in Krystal Biotech in the 1st quarter valued at approximately $29,000. Hantz Financial Services Inc. boosted its position in Krystal Biotech by 8,950.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after buying an additional 179 shares during the period. First Horizon Advisors Inc. grew its stake in shares of Krystal Biotech by 212.8% in the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock worth $34,000 after acquiring an additional 166 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its position in shares of Krystal Biotech by 128.3% during the first quarter. Smartleaf Asset Management LLC now owns 315 shares of the company’s stock worth $58,000 after acquiring an additional 177 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on KRYS shares. HC Wainwright reiterated a “buy” rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Monday, September 15th. Guggenheim set a $224.00 price target on Krystal Biotech and gave the company a “buy” rating in a research report on Friday, October 17th. Citigroup boosted their price objective on Krystal Biotech from $166.00 to $198.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Weiss Ratings restated a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday. Finally, Bank of America raised their target price on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a report on Friday, October 17th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of “Moderate Buy” and a consensus target price of $228.14.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $221.96 on Friday. The business has a 50-day moving average of $196.60 and a two-hundred day moving average of $161.80. The company has a market capitalization of $6.44 billion, a price-to-earnings ratio of 33.28 and a beta of 0.48. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $222.66.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $1.12 by $1.54. The business had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. As a group, equities research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).